Innate Pharma (STU:IDD) FFO


STU:IDD Innate Pharma SA STU:IDD
33 GF Score
Price €1.65
GF Value €0.14
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma FFO?

FFO (Funds from operations) only applies to REITs.

STU:IDD
33GF Score
Innate Pharma SA STU:IDD
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innate Pharma (STU:IDD) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of €1.65 is trading 1077.1% above its estimated GF Value™ of €0.14. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for STU:IDD:

  • FFO:
  • GF Value™: €0.14 vs. price of €1.65 (1077.1% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the STU:IDD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
33GF Score

Get the complete analysis for STU:IDD

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.65
Price
€0.14
GF Value